Sees FY25 gross margin 83%-85%. Sees positive adjusted EBITDA and cash flow in each quarter of 2025. Delcath Systems (DCTH) announced full year 2025 financial guidance and its intention to enter into a Medicaid National Drug Rebate Agreement to expand patient access.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DCTH:
- Delcath Systems Shareholders Approve Key Amendments at Meeting
- Delcath Systems: Strong Revenue Growth and Strategic Expansion Drive Buy Rating
- Delcath Systems Reports Strong Q1 2025 Growth
- Delcath Systems’ Earnings Call Highlights Growth and Challenges
- Delcath Systems reports Q1 EPS 3c, consensus 3c